Early RNA therapies like Mipomersen, a second-generation phosphorothioate ASO targeting apolipoprotein B-100, were approved for homozygous FH but discontinued due to severe liver toxicity.263. This evidence concerns the gene APOB and familial hyperaldosteronism.